Loudi Central Hospital
9
5
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
33%
3 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Tirofiban After Successful MT Recanalization in AIS
Role: collaborator
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
Role: collaborator
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Role: collaborator
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
Role: collaborator
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
Role: collaborator
Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
Role: collaborator
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Role: collaborator
A Clinical Trial of the Effectiveness and Safety of Software Assisting Diagnose the Intestinal Polyp Digestive Endoscopy by Analysis of Colonoscopy Medical Images From Electronic Digestive Endoscopy Equipment
Role: collaborator
Real-Time Artificial Intelligence Assissted Colonoscopy to Identify and Classify Polyps
Role: collaborator
All 9 trials loaded